Sinem Ezgi GÜLMEZ · 2020. 6. 29. · Prof Sinem Ezgi Gülmez, MD, PhD June 2020 3/32 3/32 INVITED EXPERTISE The Committee for Human Medicinal Products (CHMP) of the European Medicines

1/32

Sinem Ezgi GÜLMEZ

MD, PhD PROFESSOR OF MEDICAL AND CLINICAL

PHARMACOLOGY, AND PHARMACOEPIDEMIOLOGY SENIOR SCIENTIFIC COORDINATOR ON

PHARMACOEPIDEMIOLOGY

Address: Koç University, School of Medicine Department of Medical Pharmacology 1, Rumelifeneri Yolu 34450 Sariyer / ISTANBUL - TURKEY

Tel (office): +90 212 338 09 45 Mobile: +90 (0) 533 1500 376 Emails: [email protected]

[email protected] Website: www.sinemezgigulmez.com Skype: ezgigulmez ORCID ID: 0000-0001-8815-9128

PROFESSIONNAL EXPERIENCE

1 September 2018 – present University Professor of medical and clinical pharmacology, and pharmacoepidemiology Koç University, School of Medicine, Department of Medical Pharmacology, Istanbul, Turkey

21 April 2010 Professor associated of Pharmacology April 2007 – August 2017 Professor associated of Medical Pharmacology,

Senior medico-scientific coordinator Université de Bordeaux, Département Hospitalo-Universitaire de Pharmacologie du CHU de Bordeaux et de l’Université de Bordeaux, Bordeaux PharmacoEpi (Plateforme de recherche en Pharmaco-épidémiologie, BPE), CIC Bordeaux CIC1401, Bordeaux, France

April 2005 – March 2007 Research fellow University of Southern Denmark, Faculty of Health Sciences, Institute of Public Health, Research Unit of Clinical Pharmacology, Odense, Denmark

LANGUAGES

Turkish Native English Bilingual French Bilingual Danish Limited competence

NATIONALITES

French

Turkish

Prof Sinem Ezgi Gülmez, MD, PhD June 2020

2/32 2/32

EXPERTISE

Pharmacoepidemiology: Database studies (EGB, SNIIRAM, OPED, CPRC), field studies in therapeutic areas Hepatology, DILI, Gastroenterology, Cardiovascular, Pain, Elderly

Clinical pharmacology: Clinical trials in Pain, Headache, Asthma, COPD, Rheumatology

Fundamental pharmacology: In vitro isolated organ bath systems, in vitro isolated organ and cell culture studies, in vivo experimental animal models

EDUCATION

2017, May 9th PhD (pharmacoepidemiology) (via Eu2P Programme) Université de Bordeaux, Bordeaux, France

2013, December 19th Diplôme Habilitation à Diriger des Recherches (HDR) Université de Bordeaux, Bordeaux, France

2010, April 21st Qualified as University Associate Professor of Pharmacology Turkey (equivalent of an entry list of suitable University Professorship)

2001 – 2005 Specialization in medical pharmacology Ankara University Faculty of Medicine, Department of Medical Pharmacology, Ankara, Turkey

1994 – 2000 Medical Doctor (MD) Ankara University Faculty of Medicine, Ankara, Turkey

1986 – 1993 High School Ankara Atatürk Anatolian High School, Ankara, Turkey

GRANTS FOR RESEARCH PROJECTS

EURO-SALT(f): Feasibility study of EURO-SALT. Financed by public grant from ANSM (Appel à candidatures pour financer des projets de recherche sur thématiques ciblées – 1, 2015). EURO-SALT is the study of drug-exposed acute liver failure in European transplant centres, retrospectively and prospectively evaluating “10 years in 10 countries”.

SALT-III (Study of Acute Liver Transplant): Financed by public grant through ANSM (AAP-2013-029). Prospective case-population surveillance of ALFT.

SALT-II (Study of Acute Liver Transplant): Financed by Bordeaux University Foundation. A multicentre case-population study, retrospectively evaluating the risk of ALFT (Acute Liver Failure leading to registration for Transplantation) in drug-exposed patients for a 7-year period (2007 – 2014) further to the study period of SALT-I study (2005 – 2007) thus evaluating a 10-year period.

SALT-I (Study of Acute Liver Transplant): Conducted at the request of the CHMP of the European Medicines Agency. Financed by Helsinn Healthcare S.A. The study conducted independently from the financer. A multicountry multicentre case-population study, retrospectively evaluating the risk of ALFT (Acute Liver Failure leading to registration for Transplantation) in NSAID- and paracetamol-exposed patients for a 3-year period (2005 – 2007).

EPIHAM (EPIdemiology of acute HepAtotoxicity from Medicines): Financed by public funding from the Research Institute of Public Health (IReSP, Institut de Recherche en Santé Publique). EPIHAM is to identify in the national healthcare databases all hospital admissions for toxic or unexplained liver injuries.


3/32 3/32

INVITED EXPERTISE

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA). Invited as expert for the presentation of the SALT study results at the CHMP hearing meeting for Art. 31 for nimesulide. May 17th 2011, London, the United Kingdom.

La Haute Autorité de Santé (HAS), Commission de la Transparence. Invited as expert for the presentation of the results French part of the SALT study at the meeting held on May 11th 2011, Paris, France.

INVITED EXTERNAL EXPERT PUNCTUAL

Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Direction Scientifique et de la Stratégie Européenne External invited expert since 2016 (2016 and 2017) of the expert panel for the evaluation of the research projects submitted to the ANSM within the context of “Call for Projects to fund scientific research on the safety of the use of medicines and medical devices, independent of industry (l’Appel à Projets pour financer des recherches scientifiques sur la sécurité d’emploi des médicaments et dispositifs médicaux, indépendamment de l’industrie)” by the ANSM – Scientific Direction and European Strategy.

EXTERNAL EXPERT

La Haute Autorité de Santé (HAS), Service Évaluation de la Pertinence des Soins et Amélioration des Pratiques et des Parcours (SA3P), Direction de l'Amélioration de la Qualité et de la Sécurité des Soins External expert since 2017 of the Working Group “Development of a Best Practice Framework on Health Applications and Connected Objects (Mobile Health or mHealth) for the general public or patients, (Élaboration d’un Référentiel de bonnes pratiques sur les applications et les objets connectés en Santé (Mobile Health ou mHealth) à destination du grand public ou des patients)”.

INVITED TRAINER

Gülmez SE. “Rational Use of Medicines Project” between Marmara University & Turkish Social Security Institution, Training Meeting for the Turkish Social Security Institution regulators. 13-14 June 2013. Ankara, Turkey.

INVITED PRESENTATIONS

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) of the European Medicines Agency (EMA) Invited to present “EURO-SALT (Study of Acute Liver Transplant)” project at the ENCePP Plenary Session, November 22nd 2016. London, UK. Presentation published on ENCePP website: http://www.encepp.eu/publications/documents/6.1_GULMEZ-EURO-SALT-ENCePP_Plenary20161122.pdf

Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Invited to present “SALT-III (Study of Acute Liver Transplant)” project at ANSM “Journée Thématique du Conseil Scientifique, Suivi des Appels à Projets 2013 et 2014”, November 30th 2016. Paris, France.

Institut de Recherche en Santé Publique (IReSP) Invited to present EPIHAM (Epidemiology of acute hepatotoxicity from medicines) project at IReSP Séminaire de mi-parcours AAR Général 2013. 27 September 2016, Paris, France.


4/32 4/32

INVITED CONFERENCES, WEBINARS

Gülmez SE. Webinar “Clinical Trials and COVID-19”. Speech: “Epidemiologic Studies and COVID-19”. 11 June 2020. Organized by Clinical Pharmacology Working Group of the Turkish Pharmacology Society.

Gülmez SE. II. Ulusal Curly Doc Says (CDS) Tıpta Kariyer ve Bilimsel Araştırmalar Zirvesi. 17-18 November 2018, Ankara, Turkey. Gülmez SE. 8th Annual Conference of The European Epidemiological Forum (EpiFroum) “From Volume to Value, The Use of Real Word Evidence to Improve Clinical Programs and Patients’ Lives”. 8 October 2018, Zurich, Suisse. Gülmez SE. National Medical Students Research Congress by the Student Scientific Research Club of Istanbul University Cerrahpasa Faculty of Medicine (CTFÖBAK), 17-18 March 2018, Istanbul, Turkey. Invited Speaker and Chair Gülmez SE. International Conference on Science and Technology by New Turkey Strategic Research Centre (NTSRC). 2-7 October 2016, Ankara, Turkey. Invited Chair Gülmez SE. “Rational Use of Medicines in the World.” Symposium of the Turkish Rational Use of Medicines Society. 5-8 December 2013. Ankara, Turkey. Gülmez SE. “Comparative Hepatotoxicity of NSAIDs: Results from the SALT study.” Symposium of the Swiss-Austrian ISOP Chapter - Hepatotoxicity. 14 March 2013. Zurich, Switzerland. Gülmez SE. “New Pharmacovigilance Legislation: pharmacoepidemiology view”. Impact of New Pharmacovigilance Legislation - MAPI Research Group. 15 October 2012, London, UK. Gülmez SE. “Pharmacovigilance - Risk & Benefit Management in Drug Safety” Web-Conference. Kakushin Group. 30 May 2012. Gülmez SE. Rational Drug Use in the World. 5th Clinical Pharmacology Symposium at 21st National Pharmacology Congress. 19 October 2011, Eskişehir, Turkey. Gülmez SE on behalf of the SALT study group. Study of Acute Liver Transplant (SALT): Main results of the 7-country case-population study on acute liver failure associated with NSAIDs and paracetamol. ISPE 2nd Rapid Medical Product Safety Symposium Webinar. 23 June 2011. Gülmez SE. The effect of dipyrone on lung function. 4th International Symposium of Clinical Pharmacology and Therapeutics. 25-26 October 2007, Sofia, Bulgaria. “Satellite symposium on non-opiate pain reliving drugs, metamizole”.

PUBLIC CONFERENCES

“Rational Use of Medicines” Health Conference. French-Turkish Health Foundation. Bordeaux, France, 8 November 2014. “Rational Use of Medicines” Health Conference. French-Turkish Health Foundation. Bordeaux, France, 14 April 2014.

“Health System and Social Security in France” European Medical Conference, organized by the French-Turkish Health Foundation at the European Parliament. Strasbourg, France, 12 February 2014.

“Rational Use of Antibiotics” Health Conference. French-Turkish Health Foundation & Association Culturelle Atatürk Franco Turque de Bordeaux. Bordeaux, France, 14 September 2013. “Rational Use of Antibiotics” Health Conference. French-Turkish Health Foundation & ACORT Culture (L’Assemblée Citoyenne des Originaires de Turquie). Paris, France, 27 April 2013.

“Rational Use of Antibiotics” Health Conference. French-Turkish Health Foundation & Association Culturelle Trabzon de Paris. Epinay-Sur-Seine, Paris, France, 9 February 2013.


5/32 5/32

ACADEMIC ACTIVITIES

6th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 24-28 June 2003, İstanbul, Turkey. Scientific Secretariat.

3rd International Symposium Workshop on Pharmacoepidemiology & Pharmacoeconomy, 24-27 November 2004, Çeşme-İzmir, Turkey. Scientific Secretariat.

ARAMA Conference, “Rational Use of Medicines”, 6-8 March 2003, Bolu, Turkey. Scientific Secretariat

SEMINARS

Pharmacoepidemiology: Past, Present, Future (seminar in Turkish). Department of Medical Pharmacology, Marmara University Faculty of Medicine, Istanbul, Turkey, 30 May 2019.

Clinical pharmacology in Turkey. Clinical Pharmacology, Huddinge-Karolinska Institute, Stockholm, Sweden, 8 November 2006.

Proton pump inhibitors and the risk of community-acquired pneumonia. Vejle Hospital, Vejle, Denmark, 5 October 2006.

COMMITEES AT KUSOM

Committee for Careers in Medicine (CCIM), Koç University School of Medicine. Founder & Current Chairperson. February 2019 – present.

Counseling Group for Faculty Advancement (CGFA), Koç University School of Medicine. Current Chairperson. June 2019 – present.

School of Medicine Assessment Committee (SOMAC), Koç University School of Medicine. Member. March 2019 – present.

Clinical Trials Committee, Koç University School of Medicine. Member. September 2018 – present.

PROFESSIONAL MEMBERSHIPS

International Union of Basic and Clinical Pharmacology (IUPHAR) Membership Committee (since May 2018) Council Representative Delegate of Turkey at the European Association for Clinical Pharmacology and Therapeutics (EACPT) (2003 – 2011) French Pharmacology Society (SFPT) (2016-2018) International Society of Pharmacoepidemiology (ISPE) (since 2004) International Society of Pharmacovigilance (ISoP) (2011 – 2012, 2013 – 2014) Danish Society of Pharmacoepidemiology (DSFE) (2005 – 2015) Member of the Executive Committee of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – Turkish SCP Chapter (2007 – 2010) Turkish Society of Pharmacology (2001 – 2015) Clinical Pharmacology Working Group of Turkish Society of Pharmacology (2010 – 2014) PhD trainees’ representative for European Programme in Pharmacovigilance and Pharmacoepidemiology (Eu2P) (2013 – 2017) French-Turkish Health Foundation (Vice-President, 2014 – 2016)


6/32 6/32

EDITORIAL FUNCTIONS

Board Member of International Consulting Editors (BICE) of the journal “Clinical Therapeutics” (April 2014 – present) Turkish Clinics (May 2014 – present) Editor-in-Chief: The E-bulletin of Working Group of Clinical Pharmacology of the Turkish Society of Pharmacology (January – June 2012) Scientific Editor: The E-bulletin of Working Group of Clinical Pharmacology of the Turkish Society of Pharmacology (August– December 2011)

PEER-REVIEWING FOR SCI INTERNATIONAL MEDICAL JOURNALS

JAMA (The Journal of the American Medical Association) (13 manuscripts). JAMA Internal Medicine (5 manuscripts). JAMA Network Open (1 manuscript). Clinical Therapeutics (6 manuscripts). BMJ (British Medical Journal) (4 manuscripts). Pharmacoepidemiology and Drug Safety (PDS) (8 manuscripts). European Journal of Clinical Pharmacology (4 manuscripts). British Journal of Clinical Pharmacology (3 manuscripts). Basic and Clinical Pharmacology and Toxicology (14 manuscripts). Epidemiology (1 manuscript). Canadian Medical Association Journal (CMAJ) (1 manuscript). Allergy (1 manuscript). BMC Clinical Pharmacology (1 manuscript). BMC Gastroenterology (1 manuscript). British Journal of Medicine and Medical Research (1 manuscript). Journal of Population Therapeutics and Clinical Pharmacology (1 manuscript). Journal of Clinical Pharmacy and Therapeutics (1 manuscript). Journal of Medicine and Medical Sciences (1 manuscript). Journal of Clinical Toxicology (1 manuscript). European Oral Research (1 manuscript). The Eurasian Journal of Medicine (1 manuscript). African Journal of Pharmacy and Pharmacology (2 manuscripts). African Journal of Biotechnology (1 manuscript).

PEER-REVIEWING BOOKS

“Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice, 6th Edition. John Talbot (Editor), Jeffrey K. Aronson (Editor). ISBN: 978-0-470-98634-9. December 2011, Wiley-Blackwell.” Peer-reviewing for the new revised edition.

ABSTRACT REVIEWING FOR INTERNATINONAL CONGRESSES

33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 26-30, 2014, Montreal, Canada. 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), October 24-27, 2014, Taipei, Taiwan. 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), August 14-17, 2011, Chicago, Illinois.


7/32 7/32

HONNEURS, BOURSES, NOMINATIONS

1. “Outstanding Contribution in Reviewing” By the journal “Clinical Therapeutics”, awarded certificate dated November 2017 (Annexe 1).

2. “British Journal of Clinical Pharmacology Prize 2015” Nominate Nominated for the published article “Liver transplant associated with paracetamol overdose: results from the 7-country SALT study” Br J Clin Pharmacol 2015 Sep;80(3):599-606. doi: 10.1111/bcp.12635. Epub 2015 May 27.

3. “Best Reviewer” By the journal “Pharmacoepidemiology and Drug Safety”, letter dated 6 June 2014 (Annexe 2).

4. “A Personal Thank You” Letter By the journal “Pharmacoepidemiology and Drug Safety”, letter dated 4 August 2011 (Annexe 3).

5. “Outstanding Reviewer Recognition” By the journal “Pharmacoepidemiology and Drug Safety”, letter dated 7 July 2010 (Annexe 4).

6. “EACPT Scientific Award 2009” Nominate Nominated for the published article “Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study”. Arch Intern Med 2007;167:950-5.

7. “British Journal of Clinical Pharmacology Prize 2009” Nominate Nominated for the published article “Do statins protect against upper gastrointestinal bleeding?” Br J Clin Pharmacol. 2009;67(4):460-5.

8. “British Journal of Clinical Pharmacology Prize 2008” Nominate Nominated for the published article “Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study”. Br J Clin Pharmacol 2008; 66(2):294-9.

9. Young Investigator Bursary Awarded by the EACPT for the 10th EACPT Congress, 26-29 June 2011, Budapest, Hungry.

10. Young Investigator Bursary Awarded by the EACPT for the 9th EACPT Congress, 12-15 July 2009, Edinburg, UK.

11. Participation Scholarship Awarded by the EACPT for the 6th EACPT Summer School in Clinical Pharmacology and Therapeutics, “Drug Development and Drug Registration in Europe”, 14-16 July 2008, San Lorenzo de El Escorial - Madrid, Spain.

12. Poster Award Gülmez SE, Ergün H, Tulunay FC. The Waste of Drugs among Families Living in Ankara. 6th Congress of EACPT, 24-28 June 2003, İstanbul, Turkey. Abstract, p.176 (oral communication).

POSITIONS IN PRIVATE, PUBLIC OR NON-PROFIT INSTUTIONS

MENTOR AT CROSSING PATHS

Mentor at Crossing Paths (Kesişen Yollar) (2017 – present)

https://kesisenyollar.org/

https://mentornity.com/crossingpaths


8/32 8/32

MEDIA

“Yurtdışındaki Türk Bilim İnsanları: Prof. Dr. Sinem Ezgi Gülmez” Pervin Kaplan, 02/02/2017 http://www.pervinkaplan.com/detay/yurtdisindaki-turk-bilim-insanlari-prof-dr-sinem-ezgi-gulmez/2324 Bu röportaj TAF Network ekibinden Naci Aydın tarafından pervinkaplan.com için gerçekleştirildi. Bu röportajın Youtube yayınını izlemek için: https://www.youtube.com/watch?v=ibUrngs4TWc

Dünya’da Türk Hekimler ve Başarı Öyküleri: “Bordeaux Üniversitesi’nde Farmakoepidemiyoloji Alanında Çalışmalarını Sürdüren Dr. Sinem Ezgi Gülmez” Esra Öz, 22/03/2014 http://www.esraoz.com/2014/03/22/bordeaux-universitesinde/

“Sinem Ezgi Gülmez ile Tıp” Crossing Paths (Kesişen Yollar), Career Talks (Kariyer Sohbetleri), 03/03/2017 https://kesisenyollar.org/programlar/kariyer-sohbetleri/ https://www.youtube.com/watch?v=buQBHiJwNBw

WILEY Press Release (2015) Large but unexplained variations in paracetamol-induced liver failure among European countries: Six-times higher risk in Ireland and a two-fold higher risk in the UK highlighted in study https://www.wiley.com//WileyCDA/PressRelease/pressReleaseId-118382.html

Australian Medical Association “Paracetamol-induced liver failure an English-speaking problem” Kirsty Waterford, 21/07/2015 https://ama.com.au/ausmed/paracetamol-induced-liver-failure-english-speaking-problem

Läkartidningen. 2015;112:DISX Oförklarade skillnader i paracetamol-orsakad leverskada Felicia Lindberg, 01/06/2015 http://www.lakartidningen.se/Klinik-och-vetenskap/Nya-ron/2015/05/Stora-europeiska-skillnader-i-antalet-overdoser-av-paracetamol/

MEDSCAPE Acetaminophen-Linked Liver Failure Varies Widely in Europe Janis C. Kelly, 28/05/2015 https://www.medscape.com/viewarticle/845501

Science News Large but unexplained variations in paracetamol-induced liver failure among European countries… 28/05/2015 https://www.sciencedaily.com/releases/2015/05/150528084200.htm


9/32 9/32

The Daily Mail Serious paracetamol overdoses TWICE as likely to happen in Britain as in the rest of Europe Ben Spencer, Science Reporter for The Daily Mail, 28/05/2015 http://www.dailymail.co.uk/health/article-3100642/Serious-paracetamol-overdoses-TWICE-likely-happen-Britain-rest-Europe.html

Pulse Today UK paracetamol overdose rate ‘twice the European average’ Caroline Price, 29/05/2015 http://www.pulsetoday.co.uk/uk-paracetamol-overdose-rate-twice-the-european-average/20010101.article

Medical News Today Large but unexplained variations in paracetamol-induced liver failure among European countries 29/05/2015 https://www.medicalnewstoday.com/releases/294604.php

Reuters Health - NEW YORK Rates of Paracetamol-Induced Liver Failure Vary Widely in Europe Rita Buckley, 2015

The Pharmacist Paracetamol causes highest liver failure in British Isles Louise Naughton, 28/05/2015 http://www.thepharmacist.co.uk/news/news-in-brief/paracetamol-induced-liver-failure-highest-in-british-isles/

Pourquoi Docteur Le surdosage de paracétamol est une cause importante d'insuffisance hépatique nécessitant une greffe de foie. Mais les dégâts soient bien plus importants Outre-Manche. Par Anne-Laure Lebrun, 30/05/2015 https://www.pourquoidocteur.fr/Articles/Question-d-actu/10892-Paracetamol-les-overdoses-peuvent-conduire-a-une-greffe-du-foie

Hepatites Le paracétamol est un des seuls médicaments sur le marché directement hépatotoxique, y compris à des doses proches des doses recommandées 01/07/2015 http://www.hepatites.net/index.php?name=PNphpBB2&file=printview&t=23684&start=0

La Nutrition Le paracétamol toxique pour le foie : comment se prémunir http://www.lanutrition.fr/les-news/paracetamol-et-foie-comment-reduire-le-danger.html


10/32 10/32

Pharmazeutische Zeitung Leberversagen: Paracetamol gefährlichster Arzneistoff 18/06/2015 https://www.pharmazeutische-zeitung.de/2015-06/leberversagen-paracetamol-gefaehrlichster-arzneistoff/

Kurier Kritik an Paracetamol 20/06/2015 https://kurier.at/wissen/kritik-an-paracetamol/137.272.137

La Huella Hepática Del Exceso de Paracetamol en Europa LAURA TARDÓN, Madrid, 08/06/2015 https://www.elmundo.es/salud/2015/06/08/5567016546163f9f3e8b4580.html


11/32 11/32

TEACHING ACTIVITIES

PhD THESIS TUTOR

Tutor regarding the French part of the thesis of Dr. Manoj SHARMA, holder of a French “Sandwich PhD Program” grant between France and India, from 01/05/2009 to 31/12/2009. The subject of the thesis is on NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): “Pharmacovigilance Study with the use of non-steroidal anti-inflammatory drugs (NSAIDs) in special reference to Nimesulide in European population”. Publication regarding his work: Sharma M, Gülmez SE, Lassalle R, Moore N. Use of NSAIDs in France: Analysis from French reimbursement (CNAM-TS) database. Journal of Pharmacy Research 2012; 5(9):4893-96.

INTERSHIP DIRECTOR

Dr Ülkü Sur Ünal from 01/05/2015 to 31/05/2015, in pharmacoepidemiology. Publication regarding her work: Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf 2018 Nov;27(11):1174-81. doi: 10.1002/pds.4640. Epub 2018 Aug 16. PMID: 30112779

COURSES GIVEN AT MASTER PROGRAMME

• MASTER 2 Professionnel et Recherche M2PEPV UE13. Pharmacoepidemiology of NSAIDs / Presentation of SALT study. Université de Bordeaux.

• MASTER 2 Professionnel et Recherche M2PEPV UE13. Pharmacoepidemiology of NSAIDs in elderly / Presentation of CADEUS study. Université de Bordeaux.

COURSES GIVEN AT UNIVERSITIES

• Rational Use of Medicines sessions (2018 – present). Koç University School of Medicine. Monthly and interactive Rational Use of Medicines sessions for 6th-year medical students during their Public Health internship.

• RPHM 406 Rational Pharmacotherapy Clerkship (2018 – present). Koç University School of Medicine. Rational pharmacotherapy clerkship for 4th-year medical students.

• IICR 301 Block (2019 – present): Anti-bacterial Drugs; Anti-fungal Drugs. Koç University School of Medicine. Pharmacology course for 3rd-year medical students.

• MSKL 303 Block (2019 – present): Eicosanoids & Nonsteroidal Anti-inflammatory Drugs; Local Anesthetics; Neuromuscular Blockers; Dermatopharmacology; Drugs Used in the Treatment of Rheumatoid Arthritis and Gout. Koç University School of Medicine. Pharmacology course for 3rd-year medical students.

• CRVD 304 Block (2018, 2019 – present): Antianginal Drugs; Antihypertensive Drugs; Antiarrhythmic Drugs; Cardiotonic drugs (Glycosides and Others); Hypolipidemic Drugs; RAS Pharmacology; Peripheral vasodilators; Bronchodilator Drugs; Antitussives, Expectorants and Surfactants. Koç University School of Medicine. Pharmacology course for 3rd-year medical students.


12/32 12/32

• ERUD 306 Block (2018 – present): Introduction to Endocrine Pharmacology; Hypothalamic and Pituitary Hormones; ACTH, Mineralocorticoids and Inhibitors; Thyroid Hormones and Antithyroid Drugs; Vitamin D and Other Drugs Affecting Calcium Metabolism; Estrogens; Progestins; Oral and Other Contraceptives; Androgens, Anabolic Steroids and Antiandrogens. Koç University School of Medicine. Pharmacology course for 3rd-year medical students.

• Analgesics. Université de Bordeaux. Pharmacology course for maieutic students.

• Vitamins, mineral salts, iron. Université de Bordeaux. Pharmacology course for maieutic students.

• Aspirin, NSAIDs and paracetamol, central analgesics. Université de Bordeaux. Pharmacology course for 1st-year psychomotricity students.

• Cholinergic, dopaminergic systems and medications. Université de Bordeaux. Pharmacology course for 1st-year psychomotricity students.

• Classification of neurotropic agents and psychotropic agents; anxiolytics/hypnotics, anti-epileptics. Université de Bordeaux. Pharmacology course for 1st-year psychomotricity students.

• Antidepressants, thermoregulatory agents, neuroleptics. Université de Bordeaux. Pharmacology course for 1st-year psychomotricity students.

• Analgesics. PSP2 Antilles-Guyanne, RHUMATO PN session. Université de Bordeaux (Visio UAG).

• Analgesics. Université de Bordeaux. D1 UFR-2. Pharmacology course for 3rd-year medical students.

KUSOM WORKSHOP PARTICIPATIONS

KOLT WORKSHOP

KOLT Teaching Workshops for New-Coming Faculty. 12-13 September 2018. Koç University. o Effective Teaching Tips and Good Practices o Learning-Centred Course Design and Delivery o How to Teach in Active Learning Classroom (ALC) o Blackboard Intro Workshop

EDUCATOR’S WORKSHOP

o “KUSOM Educator’s Workshop: MCQ Testing and Beyond”. 4 May 2019, Koç University School of Medicine, Istanbul, Turkey.

STRATEGICAL PLANNING WORKSHOP

o KUSOM Strategical Planning Workshop – Research (2). 5 April 2019, Koç University School of Medicine, Istanbul, Turkey.

o KUSOM Strategical Planning Workshop – Research (1). 22 November 2018, Koç University School of Medicine, Istanbul, Turkey.


13/32 13/32

INTERNATIONAL PUBLICATIONS

1. Gulmez SE, Aydin V, Akici A. Footprints of Clinical Pharmacology in Turkey: Past, Present, and Future. Clin Ther. 2020 Feb;42(2):351-362. doi: 10.1016/j.clinthera.2019.12.014. Epub 2020 Jan 16. PMID: 31955969 Review.

2. Duru M, Meydan O, Kaya M, Gulmez SE. Need for Causality Assessment Tool for Drug-Induced Acute Kidney Injury. Clinical Therapeutics 2019 Aug 9. pii: S0149-2918(19)30356-X. doi: 10.1016/j.clinthera.2019.07.013. [Epub ahead of print].

3. Moore N, Duong M, Gulmez SE, Blin P, Droz C. Pharmacoepidemiology of non-steroidal anti-inflammatory drugs. Thérapie 2019 Apr;74(2):271-277. pii: S0040-5957(18)30247-6. doi: 10.1016/j.therap.2018.11.002. [Epub 2018 Nov 8] PMID: 30477749 3 citations

4. Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System. Drug Safety 2019 Apr;42(4):559-572. doi: 10.1007/s40264-018-0752-1. [Epub 2018 Oct 25] PMID: 30361989. 3 citations

5. Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Safety 2018 Nov;27(11):1174-1181. doi: 10.1002/pds.4640. Epub 2018 Aug 16. PMID: 30112779 5 citations

6. Gülmez SE. Drugs, pharmacoepidemiology, big data... Where are we, where are we going? New Turkey Strategic Research Centre (NTSRC) Science and Technology Journal 2016; July-December Special Issue, 90 (III):759-764. Invited Review

7. Duong M, Gülmez SE, Salvo F, Abouelfath A, Lassalle R, Droz C, Blin P, Moore N. Usage patterns of single-ingredient and combined paracetamol in France. Br J Clin Pharmacol 2016; 82(2):498-503. doi: 10.1111/bcp.12957. 12 citations

8. Moore N, Salvo F, Duong M, Gülmez SE. Does paracetamol still have a future in osteoarthritis? Lancet 2016; May 21;387(10033):2065-6. doi: 10.1016/S0140-6736(15)01170-8. Epub 2016 Mar 18 7 citations

9. Gülmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Thorburn D, McCormick PA, Stricker B, Toussi M, Lignot-Maleyran S, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Moore N. Liver transplant associated with paracetamol overdose: results from the 7-country SALT study. Br J Clin Pharm 2015; 80(3):599-606. doi:1 0.1 111/bcp .1263 5 41 citations Press Release: “Large but unexplained variations in paracetamol-induced liver failure among European countries: Six-times higher risk in Ireland and a two-fold higher risk in the UK highlighted in study” http://eu.wiley.com/WileyCDA/PressRelease/pressReleaseId-118382.html

10. Gülmez SE. Rational Use of Medicines Implementations in the World. Turkish Clinics J Pharmacol-Special Topics (Special Edition on Rational Use of Medicines) 2015;3(1): 34-44. Invited Review

11. Moore N, Blin P, Gülmez SE. New oral anticoagulants (NOAC) and liver injury. J Hepatol. 2014 Aug;61(2):198-9. doi: 10.1016/j.jhep.2014.05.010. Epub 2014 May 15. PMID: 24837361. 2 citations.

12. Moore N, Gülmez SE, Blin P, Lassalle R, Jové J, Théophile H, Bégaud B, Larrey D, Bénichou J. Relative risks from case-population data. Epidemiology 2013; 24(6): 935 doi: 10.1097/EDE.0b013e3182a77882. 4 citations

13. Gülmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D. Causality of drugs involved in acute liver failure leading to transplantation: Results from the Study of Acute Liver Transplant (SALT). Drug Safety 2013; 36:757-64. 4 citations.

14. Gülmez SE. The new pharmacovigilance legislation and impact on observational studies. Marmara Pharmaceutical Journal 2013; 17: 1-4. Invited Review


14/32 14/32

15. Moore N, Gülmez SE, Blin P. Is paracetamol hepatotoxic at normal doses? BMJ 2013;346:f1519 doi: 10.1136/bmj.f1519

16. Gülmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for acute liver failure in patients exposed to NSAID or paracetamol: the multinational case-population SALT study. Drug Safety 2013; 36:135-144. doi: 10.1007/s40264-012-0013-7 58 citations

17. Gülmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, deVries C, Sturkenboom M, Perez-Gutthann S, Bénichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol 2013; 69:605-616. doi: 10.1007/s00228-012-1357-8. 8 citations

18. Moore N, Gülmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B. Choice of the denominator in case-population studies: Event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiology and Drug Safety 2013 Feb;22(2):160-7. doi: 10.1002/pds.3371. 20 citations

19. Gülmez SE, Lignot-Maleyran S, Devries CS, Sturkenboom M, Micon S, Hamoud F, Blin P, Moore N. Administrative complexities for a European observational study despite directives harmonising requirements. Pharmacoepidemiol Drug Safety 2012 Feb 16; 21(8): 851–56. doi.org/10.1002/pds.3204 10 citations

20. Demircan D, Gülmez SE, Dönertaş B, Topçu I, Yılmaz H, Berkman K, Akıcı A. Use of drugs subject to controlled prescriptions: a retrospective analysis. Balkan Med J 2013; 30(1): 46-53. doi: 10.5152/balkanmedj.2012.073 1 citation.

21. Sharma M, Gülmez SE, Lassalle R, Moore N. Use of NSAIDs in France: Analysis from French reimbursement (CNAM-TS) database. Journal of Pharmacy Research 2012; 5(9):4893-96.

22. Gülmez SE. Review: Monoclonal antibodies in hematology. Turkiye Klinikleri J Hem Onc-Special Topics, 2012; 5(1):21-4.

23. Gülmez SE, Droz-Perroteau C, Lassalle R, Blin P, Bégaud B, Rossignol M, Moore N, Fourrier-Réglat A. Are traditional NSAIDs prescribed appropriately among French elderly? Results from the CADEUS cohort. Eur J Clin Pharmacol, 2011; 67(8):833-38. doi.org/10.1007/s00228-011-1015-6 3 citations

24. Gülmez SE, Moore N. The strange case of the disappearing gastroprotectors (rapid response to the article “Statin use and risk of community acquired pneumonia in older people: population based case-control study”). BMJ 2009; 338:b2137.

25. Gülmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Hallas J. Do Statins Protect Against Upper Gastrointestinal Bleeding? Br J Clin Pharmacol 2009; 67(4):460-65. doi: 10.1111/j.1365-2125.2009.03362.x. 14 citations.

26. Gülmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Hallas J. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol, 2008; 66(2):294-9. 19 citations.

27. Gülmez SE, Frederiksen H, Hallas J. Acid suppression not the only culprit of community-acquired pneumonia — Reply. Arch Intern Med. 2008;168(10):1119. doi:10.1001/archinte.168.10.1119

28. Gülmez SE, Serel S, Uluç A, Can Z, Ergün H. Dipyrone increases the blood flow of arterial dorsal skin flaps. Aesthetic Plast Surg 2008 Sep;32(5):766-70 doi: 10.1007/s00266-008-9126-x. (Erratum in: Aesthetic Plast Surg. 2008 Sep;32(5):771). 5 citations.

29. Serel S, Gülmez SE, Kaya B, Heper AO, Emiroğlu M. The effect of platelet glycoprotein IIb/IIIa receptor antagonist on survival of rat epigastric island flaps subjected to total venous occlusion. Scand J Plast Reconstr Surg Hand Surg 2008; 42(1):1-6. doi: 10.1080/02844310701667254.


15/32 15/32

30. Gülmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case control study. Arch Intern Med 2007; 167(9):950-5. doi:10.1001/archinte.167.9.950 234 citations.

31. Gülmez SE, Celik G, Misirligil Z, Tulunay FC. Dipyrone improves small airways functions in asthmatic patients with moderate airway obstruction. J Investig Allergol Clin Immunol 2007;17(4): 242-8. 3 citations.

32. Ergün H, Gülmez SE, Tulunay FC. Cost-minimisation analysis comparing topiramate with standard treatments in migraine prophylaxis. Eur Neurol 2007;58(4):215-7. doi. 10.1159/000107942 3 citations

33. Doğrul A, Gülmez SE, Deveci MS, Gül H, Ossipov MH, Porreca F, Tulunay FC. Local antinociceptive actions of non-steroidal anti-inflammatory drugs in the mouse radiant heat tail-flick test. Anesth Analg 2007;104:927-35. DOI: 10.1213/01.ane.0000258773.46897.34 22 citations

34. Gülmez SE, Gürdal H, Tulunay FC. Airway smooth muscle relaxations induced by dipyrone. Pharmacology 2006;78(4):202-8. doi. 10.1159/000096688 9 citations

35. Erdoğan F, Ergün H, Gökay NS, Gülmez SE, Bolay B, Tulunay FC. The diffusion of nimesulide (Sulidin® gel) into synovial fluid: a comparison between administration routes. Int J Clin Pharmacol Ther 2006;44(6):270-5. 2 citations

36. Gülmez SE, Tulunay FC, Beder S, Kayacan O, Karnak D. Does dipyrone have any effect on respiratory function in COPD patients? Respir Med 2006;100(5):828-34. doi. 10.1016/j.rmed.2005.09.002 4 citations

37. Tulunay FC, Ergün H, Gülmez SE, Özbenli T, Özmenoğlu M, Boz C, Erdemoğlu AK, Varlıkbaş A, Göksan B, İnan L. The efficacy and safety of dipyrone (Novalgin®) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled multi-center study. Funct Neurol 2004; 19(3):197-202. 14 citations

38. Tulunay EO, Tulunay FC, Gülmez SE, Ergün H, Demireller A. The analgesic efficacy of dipyrone during removal of nasal packings after septal surgery. The Journal of Headache and Pain 2004; 5(4):243–6.

BOOK CHAPTERS

Sinem Ezgi Gülmez. Mann’s Pharmacovigilance. Chapter 13h “Pharmacovigilance in Turkey”. Book Editor(s): Elizabeth B. Andrews, Nicholas Moore. 3rd Revised Edition, 2013. ISBN-13 978-0-470-67104-7 / 9780470671047. First published: 01 April 2014 https://doi.org/10.1002/9781118820186.ch13h

Sinem Ezgi Gülmez. “General View on Rational Use of Medicines Implementations in the World and in four European countries”. Rational Use of Medicines Implementations with Examples. Turkish Society of Rational Use of Medicines Publications, Ed. Prof. Dr. İsmail Balık, March 2015.

PUBLICATIONS IN TURKISH E-BULLETINS, PERIODICAL JOURNALS) 1. Gülmez SE. A General View on Rational Use of Medicines Implementations in the World. E-bulletin

of Turkish Clinical Pharmacology Working Group 2011; January issue. 2. Gülmez SE. Notes from the Editor and notes from the 27th ICPE. E-bulletin of Turkish Clinical

Pharmacology Working Group 2011; September issue. 3. Gülmez SE. European Union Accepted Regulations of Pharmacovigilance – New Pharmacovigilance

Directive (2010/84/EU). E-bulletin of Turkish Clinical Pharmacology Working Group 2011; February issue.

4. Gülmez SE. Clinical Pharmacology: Multidisciplinary or interdisciplinary? E-bulletin of Turkish Clinical Pharmacology Working Group 2010; July issue.

5. Gülmez SE, Tulunay FC, Ergün H. Pharmacoeconomy training in the Medical Schools in Turkey. Genel Tıp Derg 2009;19(2):65-8.

6. Gülmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Proton Pompa İnhibitörleri ve Toplum Kökenli Pnömoni Riski: Topluma Dayalı Olgu-Kontrol Çalışması. Solunum 2008;10:177- 83.


16/32 16/32

OTHER PUBLICATIONS (E-BULLETINS, PERIODICAL JOURNALS OR NEWSLETTERS) 1. Gülmez SE, Moore N. Drug-induced liver injury: Study of Acute Liver Transplant (SALT) in European

transplant centers (I risultati dello studio europeo SALT). FOCUS Pharmacovigilanza Maggio 2013; p.8. 2. Gülmez SE. New Pharmacovigilance Legislation: pharmacoepidemiological view. PRM Newsletter

2013; N°13:3-4. 3. Gülmez SE, Moore N. Drug-induced liver injury: Study of Acute Liver Transplant (SALT) in European

transplant centers. PRM Newsletter 2012; N°11:4-6. 4. Gülmez SE, Moore N. The strange case of the disappearing gastroprotectors (rapid response to the

article “Statin use and risk of community acquired pneumonia in older people: population based case-control study”). BMJ 2009; 338:b2137. doi. 10.1136/bmj.b2137

ORAL COMMUNICATIONS

1. Gülmez SE, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and non-overdose paracetamol (EPIHAM). 9th Asian Congress of ISPE (ACPE), 15-16 November 2015, Bangkok, Thailand. Proceedings of the ISPE’s 9th Asian Conference on Pharmacoepidemiology; Observational Studies for Medicine Safety & Clinical Effectiveness: A Public Health Approach; 2015; OP35, p:80.

2. Gülmez SE, Lassalle R, Jové J, Caridade G, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and non-overdose paracetamol (EPIHAM). 12th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 26-29 June 2015, Madrid, Spain. Clinical Therapeutics 2015; 37(8): Supplement, Page e15.

3. Gülmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation: Results from SALT Study (Study of Acute Liver Transplant). 13th Annual Meeting of the International Society of Pharmacovigilance (ISoP), 1-4 October 2013, Pisa, Italy. Drug Safety 2013; 36(9): 824-25.

4. Akici A, Dogukan MN, Gok H, Donertas B, Gülmez SE, Kaptanoglu AY, Karahan B, Yer M, Kutay V, Kalaca S. Drug utilisation in Turkey: First results by SGK – Medula database. International Symposium on Social Determinants of NCDs in Mediterranean Countries, 6-7 May 2013, Istanbul, Turkey. Abstract Book, page 11. Oral presentation by Sibel Kalaca.

5. Gülmez SE, Lignot S, Larrey D, deVries C, Perez-Gutthann S, Montastruc JL, Sturkenboom M, Bénichou J, Velo G, Caputi A, Salvo F, Hamoud F, Micon S, Lassalle R, Jove J, Pageaux GP, Horsmans Y, Bernuau J, Bissoli F, Stricker B, Thorburn D, Gatta A, Monteiro E, Vafiadis I, McCormick A, Metselaar A, Sen E, Nightingale A, Blin P, Moore N. Risk of acute liver failure leading to transplantation after NSAID or paracetamol exposure: Final results of the 7 European-country Study of Acute Liver Transplant (SALT). 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiology and Drug Safety 2012; 21: (Suppl. 3): 179.

6. Gülmez SE, Lignot S, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Montastruc JL, Stricker B, Thorburn D, Hamoud F, Micon S, Lassalle R, Jove J, Blin P, Moore N. Drug intoxication in patients registered for liver transplantation for acute liver failure: results from the 7-country SALT study. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiology and Drug Safety 2012; 21: (Suppl. 3): 174.


17/32 17/32

7. Gülmez SE, Lignot S, Larrey D, De Vries C, Perez-Gutthann S, Montastruc JL, Sturkenboom M, Bénichou J, Velo G, Caputi A, Salvo F, Hamoud F, Micon S, Lassalle R, Jove J, Pageaux GP, Horsmans Y, Bernuau J, Bissoli F, Stricker F, Thorburn D, Gatta A, Monteiro E, Vafiadis I, McCormick AP, Metselaar H, Sen E, Nightingale A, Blin P, Moore N. NSAID exposure and risk of acute liver failure leading to transplantation: principal results of the 7-country case-population study (SALT). 11th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2011), 26-28 October 2011, Istanbul, Turkey. Drug Safety 2011; 34(10): 895.

8. Gülmez SE, Lignot-Maleyran S, Larrey D, Pageaux GP, Hamoud F, Micon S, Lassalle R, Jove J, Bernuau J, Hormans Y, Samuel D, Benichou J, Stricker B, Bissoli F, Thorburn D, Blin P, Moore N. Role of drug exposure in patients registered for liver transplantation for acute liver failure among adults in France. 10th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 26-29 June 2011, Budapest, Hungary. Basic & Clinical Pharmacology & Toxicology 2011; 109 (Suppl. 1):46.

9. Gülmez SE, Lignot-Maleyran S, de Vries C, Sturkenboom M, S Perez-Gutthann, Bénichou J, Bissoli F, Larrey D, Pageaux GP, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. SALT-1 (Study of Acute Liver Transplant): A Study of NSAID-exposed Acute Liver Failure in Euroepan Transplant Centres. 5ème Forum Scientifique de Pharmaco-épidémiologie. 26-27 May 2011, Paris, France.

10. Gülmez SE, Lignot-Maleyran S, de Vries C, Sturkenboom M, S Perez-Gutthann, Bénichou J, Bissoli F, Larrey D, Pageaux GP, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N, on behalf of SALT-I team. SALT-I (Study Of Acute Liver Transplant): A Study of NSAID-Exposed Acute Liver Failure in European Transplant Centres. 16th World Congress of Basic and Clinical Pharmacology (WorldPharma2010), 17-23 July 2010, Copenhagen, Denmark. Basic & Clinical Pharmacology & Toxicology 2010; 107 (Suppl. 1): 121.

11. Gülmez SE, Lignot S, Micon S, Hamoud F, Blin P, Moore N. Administrative complexities for a European observational study. 20th National Congress of Pharmacology, November 4-7 2009, Manavgat-Antalya, Turkey. Abstract book, p.173.

12. Gülmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Andersen M, Hallas J. Do statins protect against upper gastrointestinal bleeding? 9th Congress of European Association for Clinical Pharmacology and Therapeutics, July 12-15 2009, Edinburgh, Scotland, the United Kingdom. Basic & Clinical Pharmacology & Toxicology 2009;105 (Suppl. 1):16.

13. Demeaux JL, Pouchain D, Lignot S, Lamarque S, Lassalle R, Bernard MA, Guillemot D, Housset B, Mayaud C, Peyramond D, Blin P, Moore N, Molimard M. Management of chronic obstructive pulmonary disease (COPD) exacerbations: results of a French cohort study. 14th WONCA Europe Regional Conference, 4-7 September 2008, Istanbul, Turkey. Abstract book, p.370. Oral presentation behalf of the study team.

14. Gülmez SE, Ergün H, Tulunay FC. The Waste of Drugs among Families Living in Ankara. 6th Congress of European Association for Clinical Pharmacology and Therapeutics, June 24-28, 2003, İstanbul, Turkey. Abstract book, p.176.


18/32 18/32

POSTER PRESENTATIONS

1. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Main Drug Classes Dispensed Prior To Hospital Admission for Acute Liver Injury. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. Pharmacoepidemiology and Drug Safety 2019;28 (S2): 1-616. Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

2. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Antibiotic Exposure Prior to Hospital Admission for Acute Liver Injury. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. Pharmacoepidemiology and Drug Safety 2019;28 (S2): 1-616. Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

3. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Antidepressant and Anxiolytic-hypnotic Exposure Prior to Hospital Admission for Acute Liver Injury. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. Pharmacoepidemiology and Drug Safety 2019;28 (S2): 1-616. Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

4. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. NSAID and analgesic exposures prior to hospital admissions for acute hepatic injury. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. Pharmacoepidemiology and Drug Safety 2019;28 (S2): 1-616. Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

5. Lignot-Maleyran S, Gulmez SE, Micon S, Lassalle R, Jové J, Droz-Perroteau C, Moore N. SALT-II: Study of acute liver transplantation in France, 2008-2013. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. Pharmacoepidemiology and Drug Safety 2019;28 (S2): 1-616. Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

6. Gulmez SE, Ozcan G, Orer HS. Fourth-year rational pharmacotherapy clerkship at Koc University School of Medicine. 14th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 22-29 June 2019, Stockholm, Sweden. Eur J Clin Pharmacol. 2019;75(Suppl 1):S59.

7. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Principales classes médicamenteuses délivrées avant une hospitalisation pour hépatite aiguë. 11e Colloque DSVR Colloque Données de Santé en Vie Réelle. 18 June 2019, Paris. Revue d'Épidémiologie et de Santé Publique, Volume 67, Supplement 4, June 2019, Page S177. https://doi.org/10.1016/j.respe.2019.04.006

8. Thurin N, Grolleau A, Duret S, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Hospitalisation pour hépatite aiguë et exposition aux antibiotiques. 11e Colloque DSVR Colloque Données de Santé en Vie Réelle. 18 June 2019, Paris. Paris. Revue d'Épidémiologie et de Santé Publique, Volume 67, Supplement 4, June 2019, Page S186. https://doi.org/10.1016/j.respe.2019.04.042

9. Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Droz-Perroteau C, Gulmez SE, Moore N. Hospitalisation pour hépatite aiguë et exposition aux antidépresseurs et benzodiazépines. 11e Colloque DSVR Colloque Données de Santé en Vie Réelle. 18 June 2019. Revue d'Épidémiologie et de Santé Publique, Volume 67, Supplement 4, June 2019, Page S187. https://doi.org/10.1016/j.respe.2019.04.044


19/32 19/32

10. Moore N, Grolleau A, Duret S, Thurin N, Duong M, Lassalle R, Blin P, Gulmez SE, Droz-Perroteau C. Hospitalisation pour hépatite aiguë et exposition aux anti-inflammatoires non stéroïdiens et aux analgésiques. 11e Colloque DSVR Colloque Données de Santé en Vie Réelle. 18 June 2019, Paris. Revue d'Épidémiologie et de Santé Publique, Volume 67, Supplement 4, June 2019, Page S187. https://doi.org/10.1016/j.respe.2019.04.043

11. Ozcan G, Gulmez SE, Orer HS. Self-efficacy surveys as a feedback tool to assess student engagement in skill training. ORPHEUS Conference 2019: Quality Training Environments for Biomedical Researchers. 21-23 March 2019, Dublin, Ireland. Abstract Book, p.19.

12. Gülmez SE, Lignot-Maleyran S, Micon S, Lassalle R, Jové J, Moore N. Future Perspectives of Study of Acute Liver Transplant (SALT): What Is Going on Since 2007? 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2016, Dublin, Ireland. Pharmacoepidemiology and Drug Safety September 2016 Special Issue: Abstracts of the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 25(Supplement S3): 601-602.

13. Gülmez SE, Lignot-Maleyran S, Micon S, Lassalle R, Jové J, Moore N. SALT-III: Prospective Study of Drug-Exposed Acute Liver Failure (ALF). 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2016, Dublin, Ireland. Pharmacoepidemiology and Drug Safety September 2016 Special Issue: Abstracts of the 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 25(Supplement S3): 602.

14. Gülmez SE, Lignot-Maleyran S, Micon S, Lassalle R, Jové J, Moore N. Future Perspectives of Study of Acute Liver Transplant (SALT): What Is Going on Since 2007? 20e Congrès de la Société Française de Pharmacologie et de Thérapeutique (SFPT 2016), 19-21 April 2016, Nancy, France. Fundamental & Clinical Pharmacology 2016 ; 30(S1) : 60

15. Gülmez SE, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and non- overdose paracetamol (EPIHAM). 20e Congrès de la Société Française de Pharmacologie et de Thérapeutique (SFPT 2016), 19-21 April 2016, Nancy, France. Fundamental & Clinical Pharmacology 2016 ; 30(S1) :51

16. Gülmez SE, Lassalle R, Jové J, Caridade G, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and non-overdose paracetamol (EPIHAM). 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 21-26 August 2015, Boston, USA. Pharmacoepidemiology and Drug Safety September 2015 Special Issue: Abstracts of the 31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 24(Supplement S1): 338. DOI: 10.1002/pds

17. Kalaca S, Dogukan MN, Gok H, Gülmez SE, Özcan F, Donertas F, Kaptanoglu AY, Yer M, Akıcı A. Cold preparations Use in Turkey: a Large Descriptive Study of SGK-Medula Database. 13th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2013), 1-4 October 2013, Pisa, Italy. Drug Safety 2013; 36(9): 866.

18. Gülmez SE, Larrey D, Pageaux GP, Jove J, Lassalle R, Lignot S, Blin P, Moore N. Drug-associated Acute Liver Failure Leading to Registration for Transplantation in France from the SALT Study, 2005-2007. 11th Congress of European Association for Clinical Pharmacology and Therapeutics, 28-31 August 2013, Geneva, Switzerland. Clinical Therapeutics 2013; 35(Suppl. 8): e27.

19. Gülmez SE, Larrey D, Pageaux GP, Jove J, Lassalle R, Lignot S, Blin P, Moore N. Drug-associated Acute Liver Failure Leading to Registration for Transplantation in France from the SALT Study, 2005-2007. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2013, Montreal, Canada. Pharmacoepidemiology and Drug Safety 2013; 22: (Suppl. 1): 49.


20/32 20/32

20. Gülmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Micon S, Hamoud F, Droz-Perroteau C, Blin P, Moore N. Risk of acute liver failure leading to transplantation after NSAID or paracetamol exposure: Study of Acute Liver Transplant (SALT). European Congress of Epidemiology (EuroEpi 2013), 11-14 August 2013, Aarhus, Denmark. Eur J Epidemiol 2013; 28:S108, DOI 10.1007/s10654-013-9820-0.

21. Gülmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey L. Causality of drugs involved in acute liver failure leading to transplantation: Results from the Study of Acute Liver Transplant) (SALT). European Congress of Epidemiology (EuroEpi 2013), 11-14 August 2013, Aarhus, Denmark. Eur J Epidemiol 2013; 28:S109, DOI 10.1007/s10654-013-9820-0.

22. Gülmez SE, Larrey D, Pageaux GP, Jove J, Lassalle R, Lignot S, Blin P, Moore N. Drug-associated acute liver failure leading to registration for transplantation in France from the Study of Acute Liver Transplant (SALT). European Congress of Epidemiology (EuroEpi 2013), 11-14 August 2013, Aarhus, Denmark. Eur J Epidemiol 2013; 28:S109, DOI 10.1007/s10654-013-9820-0.

23. Gülmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Hamoud F, Micon S, Blin P, Moore N. Choice of the Denominator for Case-Population Studies: Event Rates for Registration for Liver Transplantation in Acute Liver Failure Associated with NSAIDs or paracetamol in France in the SALT Study. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 23-26 August 2012, Barcelona, Spain. Pharmacoepidemiology and Drug Safety 2012; 21: (Suppl. 3): 412.

24. Gülmez SE, Lignot S, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, Montastruc JL, Stricker B, Thorburn D, Hamoud F, Micon S, Lassalle R, Jové J, Blin P, Moore N. Drug intoxication in patients registered for liver transplantation for acute liver failure: results from 7-country SALT study. VIIème Congrès de Physiologie de Pharmacologie et de Thérapeutique (P2T), 4-6 April 2012, Dijon, France. Fundamental and Clinical Pharmacology 2012;26 (Suppl. 1):78.

25. Gülmez SE, Lignot S, Larrey D, Pageaux GP, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Hamoud F, Micon S, Blin P, Moore N. Role of drugs in acute liver failure leading to transplantation: Results from the 7- country Study of Acute Liver Transplant (SALT). 11th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2011), 26-28 October 2011, Istanbul Turkey. Drug Safety 2011; 34(10): 950-51.

26. Gülmez SE, Lignot S, Larrey D, de Vries C, Perez-Gutthann S, Montastruc J, Sturkenboom M, Bénichou J, Velo G, Caputi A, Salvo F, Hamoud F, Micon S, Lassalle R, Jove J, Pageaux GP, Horsmans Y, Bernuau J, Bissoli F, Stricker B, Thorburn D, Gatta A, Monteiro E, Vafiadis I, McCormick A, Metselaar A, Sen E, Nightingale A, Blin P, Moore N. NSAID exposure and risk of acute liver failure leading to transplantation: Preliminary results of the Study of Acute Liver Transplant (SALT) in 7 European countries. 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 14-17 August 2011, Chicago, Illinois, USA. Pharmacoepidemiology and Drug Safety 2011; 20: S305.

27. Gülmez SE, Lignot S, Larrey D, Pageaux GP, Hamoud F, Micon S, Lassalle R, Jové J, Bernuau J, Horsmans Y, Montastruc JL, Samuel D, Bénichou J, Stricker B, Bissoli F, Thorburn D. Role of drug exposure in patients registered for liver transplantation for acute liver failure among adults in France. VIème Congrès de Physiologie de Pharmacologie et de Thèrapeutique (P2T), 22-24 March 2011, Grenoble, France. Fundamental and Clinical Pharmacology 2011; 25 (Suppl. 1), 66.

28. Gülmez SE, Lignot S, de Vries C, Sturkenboom M, Perez-Gutthann S, Bénichou J, Bissoli F, Larrey D, Pageaux GP, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. SALT-I (Study of Acute Liver Transplant): A study of NSAID-exposed acute liver failure in European transplant centres. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 19-22 August 2010, Brighton, England, the United Kingdom. Pharmacoepidemiology and Drug Safety 2010; 19: S312. DOI: 10.1002/pds


21/32 21/32

29. Gülmez SE, Lignot S, de Vries C, Sturkenboom M, Blin P, Moore N. Administrative Complexities for a European Observational Study. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 19-22 August 2010, Brighton, England, the United Kingdom. Pharmacoepidemiology and Drug Safety 2010; 19: S177. DOI: 10.1002/pds

30. Gülmez SE, Pageaux GP, Larrey D, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. SALOME: A pilot study to test causality assessment of drug-exposed acute liver failure cases using different scales. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 19-22 August 2010, Brighton, England, the United Kingdom. Pharmacoepidemiology and Drug Safety 2010; 19: S85. DOI: 10.1002/pds

31. Sharma M, Gülmez SE, Lassalle R, Moore N. Use of NSAIDs in France: Analysis from Reimbursement (CNAM-TS) Database. 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 19-22 August 2010, Brighton, England, the United Kingdom. Pharmacoepidemiology and Drug Safety 2010; 19: S171. DOI: 10.1002/pds

32. Gülmez SE, Lignot S, Micon S, Hamoud F, de Vries C, Sturkenboom M, Blin P, Moore N. Administrative complexities for a European observational study. 16th World Congress of Basic and Clinical Pharmacology (WorldPharma2010), 17-23 July 2010, Copenhagen, Denmark. Basic & Clinical Pharmacology & Toxicology 2010; 107 (Suppl. 1):313.

33. Salvo F, Pariente A, Gulmez SE, Guillaume Y, Jordi C, Sturkenboom MC, Haag M, Moore N, Fourrier-Reglat A. The SOS Project (Safety of NSAIDs): Preliminary Results of Published Meta-Analyses Review. 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 15-19 August 2009, Providence, Rhode Island, USA. Pharmacoepidemiology and Drug Safety 2009;18: S207-S208.

34. Gülmez SE, Droz-Perroteau C, Lassalle R, Moore N, Fourrier-Réglat A. Are traditional NSAIDs prescribed appropriately among French elderly? Results from the CADEUS cohort. 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 17-20 2008, Copenhagen, Denmark. Pharmacoepidemiology and Drug Safety 2008; 17:S217.

35. Gülmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Hallas J. Spironolactone use and the risk of upper gastrointestinal bleeding: A population-based case-control study. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), August 29-1 September 2007, Amsterdam, the Netherlands. Basic & Clinical Pharmacology & Toxicology 2007;101(Suppl. 1):172.

36. Tulunay FC, Malhan S, Gülmez SE. Chronic pain in Turkey. 8th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), August 29-1 September 2007, Amsterdam, the Netherlands. Basic & Clinical Pharmacology & Toxicology 2007;101(Suppl.1):5.

37. Gülmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: A Case Control Study. 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 24-27, 2006, Lisbon, Portugal. Pharmacoepidemiology and Drug Safety August 2006; 15 (Issue S1):S77.

38. Tulunay FC, Gülmez SE, Ergun H. Should pharmacoeconomy be a part of undergraduate education at medical schools? 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), June 25–29, 2005, Poznan, Poland. Basic & Clinical Pharmacology & Toxicology (Proceedings of the 7th Congress of European Association for Clinical Pharmacology and Therapeutics) 2005; 97(Suppl. I):p. 28.

39. Ergun H, Gülmez SE, Tulunay FC. Has topiramate advantages in migraine prophylaxis? 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), June 25–29, 2005, Poznan, Poland. Basic & Clinical Pharmacology & Toxicology (Proceedings of the 7th Congress of European Association for Clinical Pharmacology and Therapeutics) 2005; 97 (Suppl.I):90.


22/32 22/32

40. Ergun H, Erdoğan F, Gökay NS, Gülmez SE, Bolay B, Tulunay FC. The presence of nimesulide in synovial fluid: a comparison between administration routes. 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), June 25–29, 2005, Poznan, Poland. Basic & Clinical Pharmacology & Toxicology (Proceedings of the 7th Congress of European Association for Clinical Pharmacology and Therapeutics) 2005; 97 (Suppl. I):98.

41. Gülmez SE, Celik G, Misirligil Z, Tulunay FC. Does dipyrone have an effect on pulmonary functions in patients with asthma? 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), June 25–29, 2005, Poznan, Poland. Basic & Clinical Pharmacology & Toxicology (Proceedings of the 7th Congress of European Association for Clinical Pharmacology and Therapeutics) 2005; 97 (Suppl. I):100.

42. Gülmez SE, Gurdal H, Tulunay FC. The role of phospholipase C activity in smooth muscle relaxing effect of dipyrone. 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), June 25–29, 2005, Poznan, Poland. Basic & Clinical Pharmacology & Toxicology (Proceedings of the 7th Congress of European Association for Clinical Pharmacology and Therapeutics) 2005; 97 (Suppl. I): 100.

43. Tulunay FC, Gülmez SE, Ergün H. Reimbursement Policy in Turkey: New Consensus. ISPOR 7th Annual European Congress, October 24-26, 2004, Hamburg, Germany. Value in Health, 2004; 7(6):710-11.

44. Erdoğan F, Gökay NS, Gülmez SE, Tulunay FC. The Efficacy and Safety of Nimesulide Gel (Sulidin®) in Gonarthrosis: A Pilot Study. 8th World Conference on Clinical Pharmacology and Therapeutics, August 1-6, 2004, Brisbane, Australia. Clinical and Experimental Pharmacology and Physiology, August 2004; 31 (Suppl.1): A67.

45. Koçyiğit D, Gülmez SE, Kaya M, Ergün H, Mocan A, Tulunay FC. Efficacy & Safety of Pre-emptive Celecoxib, Rofecoxib or Dipyrone Treatment in Third Molar Surgery: Preliminary Report. 8th World Conference on Clinical Pharmacology and Therapeutics, August 1-6, 2004, Brisbane, Australia. Clinical and Experimental Pharmacology and Physiology, August 2004; 31(Suppl.1):A67.

46. Gülmez SE, Tulunay FC, Beder S, Kayacan O, Karnak D. The Effect of Dipyrone on Respiratory Function in Chronic Obstructive Pulmonary Disease (COPD). The European Respiratory Society 14th Annual Congress, September 4-8, 2004, Glasgow, Scotland. European Respiratory Journal 2004; 24 (Suppl.48):290s.

47. Gülmez SE, Ergün H, Tulunay FC. First Line Pharmacotherapy Preferences among Turkish General Practitioners in Pain Management. 20th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 22-25, 2004, Bordeaux, France. Pharmacoepidemiology and Drug Safety, July 2004;13 (Suppl.1):S58.

48. Doğrul A, Gülmez SE, Ossiopov MH, Porreca F, Tulunay FC. NSAIDs Sensitive to Radiant Tail Flick Test When Given Peripherally. 6th Congress of European Association for Clinical Pharmacology and Therapeutics, June 24-28, 2003, İstanbul, Turkey. Abstract book, p.134.

49. Tulunay EÖ, Tulunay FC, Gülmez SE, Ergün H, Demireller A: The Pre-emptive Analgesic Efficacy of Dipyrone (Novalgin®) During Removal of Nasal Packings After Septal Surgery, 6th Congress of European Association for Clinical Pharmacology and Therapeutics, June 24-28, 2003, İstanbul, Turkey. Abstract book, p.177.

50. Ergün H, Gülmez SE, Tulunay FC. Prescription Knowledge of Turkish Medical Doctors. 6th Congress of European Association for Clinical Pharmacology and Therapeutics, June 24-28, 2003, İstanbul, Turkey. Abstract book, p.176.


23/32 23/32

H-INDEX

Web of Science, June 2020: 10

Average citations per item: 9.41

Sum of Times Cited: 508 (without self-citations: 466)

Total publications:

Sum of Times Cited per Year:


24/32 24/32

PARTICIPATIONS (CONGRESSES, SEMINAIRES, SYMPOSIUMS, COURS, TRAINING, WORKSHOPS) 1. 36th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

(ICPE), 26-30 August 2020. VIRTUAL CONFERENCE “ICPE 2020 ALL ACCESS”. 2. 14th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT),

26-29 June 2019, Stockholm, Sweden. Poster presentation 3. KUSOM Educator’s Workshop: MCQ Testing and Beyond. 4 May 2019, Koç University School of

Medicine, Istanbul, Turkey. 4. KUSOM Strategical Planning Workshop – Research (2). 5 April 2019, Koç University School of

Medicine, Istanbul, Turkey. 5. KUSOM Strategical Planning Workshop – Research (1). 22 November 2018, Koç University School of

Medicine, Istanbul, Turkey. 6. II. Ulusal Curly Doc Says (CDS) Tıpta Kariyer ve Bilimsel Araştırmalar Zirvesi. 17-18 November 2018,

Ankara, Turkey. Invited Speaker 7. 8th Annual Conference of The European Epidemiological Forum (EpiFroum) “From Volume to Value,

The Use of Real Word Evidence to Improve Clinical Programs and Patients’ Lives”. 8 October 2018, Zurich, Suisse. Invited Speaker

8. Koç University KOLT Teaching Workshops for New-Coming Faculty. 12-13 September 2018, Istanbul, Turkey.

9. National Medical Students Research Congress by the Student Scientific Research Club of Istanbul University Cerrahpasa Faculty of Medicine (CTFÖBAK), 17-18 March 2018, Istanbul, Turkey. Invited Speaker and Chair

10. Bordeaux Pharmacoepidemiology Festival 2017, 10-12 May 2017, Bordeaux, France. 11. 21e Congrès de la Société Française de Pharmacologie et de Thérapeutique (SFPT 2017),

19-21 April 2017, Rouen, France. 12. ANSM Journée Thématique du Conseil Scientifique Suivi des Appels à Projets 2013 et 2014,

30 November 2016, Paris, France. Invited presentation 13. ENCePP Plenary Meeting, 22 November 2016, London, UK. Invited presentation 14. Formation Nationale MediaTraining Scientifique, 10-11 October 2016, Paris, France. 15. International Conference on Science and Technology by New Turkey Strategic Research Centre

(NTSRC). 2-7 October 2016, Ankara, Turkey. Invited Chair 16. IReSP Séminaire de mi-parcours « AAR Général 2013". 27 September 2016, Paris, France.

Invited Presentation 17. 32nd Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

(ICPE), 25-29 August 2016, Dublin, Ireland. Poster presentations 18. Formation SNIIRAM, 6 June 2016, Tours, France. 19. 20e Congrès de la Société Française de Pharmacologie et de Thérapeutique (SFPT 2016), 19-21 April

2016, Nancy, France. Poster presentations 20. 3rd Assembly of Turkish Scientists Abroad, 23-24 December 2015, Istanbul, Turkey. Invited by

TUBITAK, the Scientific and Technological Research Council of Turkey. 21. 9th Asian Congress of ISPE (ACPE), 15-16 November 2015, Bangkok, Thailand. Oral communication 22. 2nd Turkish Medical Council, 29 – 31 October 2015, Istanbul, Turkey.

Invited by the Turkish Ministry of Health. 23. 23th National Congress of Pharmacology, 7-10 September 2015, Ankara, Turkey.

Poster presentation 24. 31st Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

(ICPE), 22-26 August 2015, Boston, USA. Poster presentation


25/32 25/32

25. 12th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 26-29 June 2015, Madrid, Spain. Oral communication

26. 7ème séminaire scientifique de Pharmaco-épidémiologie, Association des Epidémiologistes de Langue Française (ADELF), 11 June 2015, Paris, France. Poster presentation

27. ISPE Mid-Year Meeting 2015, 12-14 April 2015, Bordeaux, France. 28. Bordeaux Pharmacoepidemiology Festival 2015, 14-16 April 2015, Bordeaux, France. 29. P2T 20ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (P2T 2015),

21-23 April 2013, Caen, France. 30. P2T 19ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (SFPT 2014),

22-24 April 2013, Poitiers, France. Poster presentation 31. 1st Turkish Medical Council, 29 October–2 November 2014, Istanbul, Turkey.

Invited by the Turkish Ministry of Health 32. Conférence Médical Européen, Parlement Européen, 9 February 2014, Strasbourg, France.

Invited speaker and conference organizer 33. ATSEF Meeting, 13-14 December 2013, London, UK. 34. Turkish Society of Rational Use of Medicines, “Symposium on Rational Rational Use of Medicines &

Actual Problems on RUM & Workshop on New Health Implementation”, 5-8 December 2013, Ankara, Turkey. Invited speaker

35. 13th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2013), 1-4 October 2013, Pisa, Italy. Oral communication

36. 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT), 28-31 August 2013, Geneva, Switzerland. Poster presentation

37. 29th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 25-28 August 2013, Montreal, Canada. Poster presentation

38. European Congress of Epidemiology (EuroEpi), 11-14 August 2013, Aarhus, Denmark. Poster presentations

39. 6ème séminaire scientifique de Pharmaco-épidémiologie, Association des Epidémiologistes de Langue Française (ADELF), 27-28 June 2013, Paris, France. Poster presentations

40. P2T 18ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (P2T 2013), 22-24 April 2013, Angers, France. Poster presentations

41. Bordeaux Pharmacoepidemiology Festival. 8-10 April 2013, Bordeaux, France. 42. Impact of New Pharmacovigilance Legislation- MAPI Research Group. 15 October 2012, London, UK.

Invited speaker 43. 28th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

(ICPE), 22-26 August 2012, Barcelona, Spain. Oral communications 44. P2T 17ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (P2T 2012),

4-6 April 2012, Dijon, France. Poster presentations 45. 11th Annual Meeting of the International Society of Pharmacovigilance (ISoP 2011), 26-28 October

2011, Istanbul Turkey. Oral communication & poster presentations 46. 5th Clinical Pharmacology Symposium at 21st Turkish National Pharmacology Congress.

19 October 2011, Eskişehir, Turkey. Invited speaker 47. 27th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management

(ICPE), 14-17 August 2011, Chicago, Illinois, USA. Poster presentations 48. 10th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT),

26-29 June 2011, Budapest, Hungary. Oral communication 49. 5ème séminaire scientifique de Pharmaco-épidémiologie, Association des Epidémiologistes de Langue

Française (ADELF), 26-27 May 2011, Paris, France. Oral communication


26/32 26/32

50. P2T 16ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (P2T 2011), 23-25 April 2011, Grenoble, France. Poster presentations

51. 26th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 19-22 August 2010, Brighton, UK. Poster presentations

52. 16th World Congress of Basic and Clinical Pharmacology (WorldPharma2010), 17-23 July 2010, Copenhagen, Denmark. Oral communication & poster presentations

53. 14ème Congrès de la Société Française de Pharmacologie et de Thérapeutique (P2T 2010), 23-25 April 2010, Bordeaux, France. Poster presentations

54. 20th National Congress of Pharmacology, 4-7 November 2009, Manavgat-Antalya, Turkey. Oral communication & poster presentation

55. 9th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 12-15 July 2009, Edinburgh, UK. Oral communication

56. 4ème séminaire scientifique de Pharmaco-épidémiologie, Association des Epidémiologistes de Langue Française (ADELF), 14-15 May 2009, Paris, France.

57. 14th WONCA Europe Regional Conference, 4-7 September 2008, Istanbul, Turkey. Oral communication on behalf of the study team

58. 24th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 17-20 August 2008, Copenhagen, Denmark. Poster presentation

59. 6th EACPT Summer School in Clinical Pharmacology and Therapeutics, “Drug Development and Drug Registration in Europe”. 14-16 July 2008, San Lorenzo de El Escorial - Madrid, Spain.

60. 4th International Symposium of Clinical Pharmacology and Therapeutics, Evidence based medicine and more: Individualization of drug therapy. 25-26 October 2007 Sofia, Bulgaria. Invited speaker

61. 8th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 28 August - 1 September 2007, Amsterdam, the Netherlands. Poster presentations

62. 2e Congrès Commun de la Société de Physiologie et de la Société Française de Pharmacologie et de Thérapeutique (P2T 2007), 11-13 April 2007, Toulouse, France.

63. Dansk Selskab for Farmakoepidemiologi-Årsmøde og generalforsamling. Hensigtsmæssig medicinering hos ældre. 16 November 2006, Odense, Denmark.

64. 22nd Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-27 August 2006, Lisbon, Portugal. Poster presentations

65. 1st National Workshop on Pharmacovigilance, 20-23 November 2005, İstanbul, Turkey. 66. 4th International Workshop on Pharmacoeconomics & Pharmacoepidemiology,

17-20 November 2005, İstanbul. 67. 7th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT),

25-29 June 2005, Poznan, Poland. Poster presentations 68. 60-Year Anniversary Symposium of Basic and Clinical Pharmacology and Toxicology (BCPT), “Current

Controversies in Pharmacoepidemiology”, 27-28 May 2005, Koldingfjord, Denmark. 69. Danish Clinical Intervention Research Academy’s Course (DIRAC), Pharmacoepidemiology,

22-26 May 2005, Middlefart, Denmark. 70. Turkish Society of Pharmacology, Intergeneration Education Seminars, Prof. Dr. Şahin Akman

Meeting, 2-4 March 2005, Kızılcahamam-Ankara, Turkey. 71. Turkish Pharmacological Society, Clinical Pharmacology Study Group, Rational Pharmacotherapy

Symposiums Series-5, Rational Drug Use in Paediatrics, 17 December 2004, Ankara, Turkey. 72. Danish Clinical Intervention Research Academy’s Course (DIRAC), Economic Evaluation of Health Care

Programmes, 6th December 2004, Odense, Denmark. 73. 3rd International Symposium Workshop on Pharmacoepidemiology and Pharmacoeconomics,

24-27 November 2004, Çeşme-İzmir, Turkey. Scientific secretariat


27/32 27/32

74. 20th Annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 22-25 August 2004, Bordeaux, France. Poster presentation

75. Turkish Society of Clinical Pharmacology, the Reimbursement Policy Meeting, 30 April-2 May 2004, Ilgaz-Kastamonu, Turkey.

76. Turkish Pharmacological Society, 17th National Congress of Pharmacology, 1st Clinical Pharmacology Symposium & Joint Meeting of the Turkish & Dutch Pharmacological Societies, 17-21 October 2003, Antalya, Turkey.

77. 6th Congress of European Association for Clinical Pharmacology and Therapeutics (EACPT), 24-28 June 2003, İstanbul, Turkey. Scientific secretariat. Oral communication & Poster presentations

78. ARAMA Conference, Rational Drug Use, 6-8 March 2003, Bolu, Turkey. Scientific secretariat 79. Turkish Society of Clinical Pharmacology, Rational Drug Use Conferences. Scientific secretariat 80. 6th European Headache Federation Congress, 26-30 June 2002, İstanbul, Turkey. 81. Turkish Society of Pharmacology, Intergeneration Education Seminars, 20-22 March 2002, Ilgaz-

Kastamonu, Turkey. 82. 1st EACPT European Clinical Pharmacology Summer School, 31 October–4 November 2001, Antalya,

Turkey.


28/32 28/32

ANNEXE I: “Outstanding Contribution in Reviewing” by the journal “Clinical Therapeutics”


29/32 29/32

ANNEXE II: “Best Reviewer” by the journal “Pharmacoepidemiology and Drug Safety”

June 6, 2014 Dear Dr. Sinem Gulmez, We write to thank you for the exceptionally fine quality of your peer reviewing for Pharmacoepidemiology and Drug Safety of manuscripts submitted during 2013. The strength of our journal, like all peer-reviewed journals, depends in large measure on our reviewers’ abilities and efforts. As editors, we weigh your comments carefully. While a superb review is the product of both expertise and commitment, it is also a remarkably anonymous accomplishment. The editors and the author of a paper appreciate the help a good critique provides, but under the present peer review system the author rarely knows the identity of the reviewer, and deans, departmental chairs, division chiefs, and tenure and promotion committees are often totally unaware of the amount and quality of this important academic work. We would like to offer you the opportunity to change this. Not all reviews and reviewers are of the same high quality. We grade each review, and we know our best reviewers. You are one of them. The quality and timeliness of your review for Pharmacoepidemiology and Drug Safety placed the work you did for us among the best of all reviews in 2013. We thank you, and wish to inspire you to sustain your high standards. Further, because we are interested in giving more credit to reviewers like you who provide exceptional service to medical science in this important role, I would encourage you to send a copy of this letter to others who should be aware of it, and to note on your curriculum vitae (CV) the honor conveyed by it. Again, many thanks for your fine help. Not only have the editors and authors benefited, but so have the journal’s readers and, ultimately, medical science. Sincerely,

Brian L Strom Editor-in-Chief

Joerg Hasford Regional Editor for Europe

Sean Hennessy Regional Editor for the Americas

Byung Joo Park Regional Editor for Asia, Africa, the Middle East and Oceania

EDITOR-IN-CHIEF Professor Brian L. Strom M.D. M.P.H. Chancellor, Rutgers Biomedical & Health Sciences Rutgers, the State University of New Jersey 65 Bergen Street, Suite 1535 Newark, NJ 07103 Phone: (973) 972-4400 Email: [email protected]


30/32 30/32

ANNEXE III: “A Personal Thank You” by the journal Pharmacoepidemiology and Drug Safety


31/32 31/32

ANNEX IV: “Outstanding Reviewer Recognition” by the journal Pharmacoepidemiology and Drug Safety


32/32 32/32

ANNEXE V: “Advanced Level GCP” Certificate

Documents

Sinem Ezgi GÜLMEZ · 2020. 6. 29. · Prof Sinem Ezgi Gülmez, MD, PhD June 2020 3/32 3/32 INVITED EXPERTISE The Committee for Human Medicinal Products (CHMP) of the European Medicines